Delving into the Latest Updates on Pegylated integrated interferon mutant (Beijing Tri-Prime Gene) with Synapse

Overview

Basic Info

Drug Type

Interferons

Synonyms

PEG-IIFNm

Target

IFNAR

Action

agonists, stimulants, inducers

Mechanism

IFNAR agonists(Interferon alpha/beta receptor agonists), Immunostimulants, Innate antiviral immune response inducers

Therapeutic Areas

Infectious DiseasesDigestive System Disorders

Active Indication

Hepatitis, Viral, HumanHepatitis, Chronic

Inactive Indication-

Originator Organization

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd.

Active Organization

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

To evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of multiple doses of a novel integrated interferon mutant injection of polyethylene glycol in healthy adult subjects and patients with chronic hepatitis B, and to provide a theoretical basis for the dosing regimen of subsequent clinical trials.

Start Date10 Apr 2023

Sponsor / Collaborator

Beijing Biaiou Technology Development Co Ltd

[+1]

CTR20222911

/ RecruitingPhase 1

聚乙二醇新型集成干扰素突变体注射液在中国健康人中单次给药的耐受性和药代动力学/药效动力学研究

[Translation] Tolerability and pharmacokinetic/pharmacodynamic study of a single-dose pegylated novel integrated interferon mutant injection in healthy Chinese subjects

评价聚乙二醇新型集成干扰素突变体注射液单次给药在健康成年受试者中的安全性、耐受性和药代动力学（PK）/药效动力学（PD）特征，为后续临床试验的给药方案提供理论依据。

[Translation]

To evaluate the safety, tolerability, and pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of a single dose of a novel integrated interferon mutant injection containing polyethylene glycol in healthy adult subjects, and to provide a theoretical basis for the dosing regimen of subsequent clinical trials.

Start Date08 Oct 2022

Sponsor / Collaborator

Beijing Biaiou Technology Development Co Ltd

[+1]

CTR20132248

/ Active, not recruitingPhase 1

聚乙二醇新型集成干扰素突变体注射液多次给药的耐受性、药代动力学和药效动力学的临床研究

[Translation] Clinical study on the tolerability, pharmacokinetics and pharmacodynamics of multiple-dose PEGylated novel integrated interferon mutant injection

考察PEG-IIFNm多次给药人体药代动力学和药效动力学特征

[Translation]

To investigate the pharmacokinetic and pharmacodynamic characteristics of PEG-IIFNm after multiple administration in humans

Start Date14 May 2013

Sponsor / Collaborator

Beijing Biaiou Technology Development Co Ltd

[+1]

100 Clinical Results associated with Pegylated integrated interferon mutant (Beijing Tri-Prime Gene)

Login to view more data

100 Translational Medicine associated with Pegylated integrated interferon mutant (Beijing Tri-Prime Gene)

Login to view more data

100 Patents (Medical) associated with Pegylated integrated interferon mutant (Beijing Tri-Prime Gene)

Login to view more data

100 Deals associated with Pegylated integrated interferon mutant (Beijing Tri-Prime Gene)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatitis, Viral, Human	Phase 2	China	Beijing Tri-Prime Gene Pharmaceutical Co., Ltd.	10 Apr 2023
Hepatitis, Chronic	Phase 1	China	Beijing Tri-Prime Gene Pharmaceutical Co., Ltd.	28 Apr 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data